Mylan Pharmaceuticals named in class action lawsuit over price gauging EpiPen

Mylan Pharmaceuticals



At the heart of this proposed class action is a pharmaceutical corporation seeking to boost profits at the expense of families who need the lifesaving product it sells. The product at issue is the EpiPen®, a lifesaving emergency auto-injector treatment for millions of people who suffer from severe allergies and are at risk for anaphylaxis. Anaphylaxis is a potentially life-threatening allergic reaction that can occur quickly, sometimes within minutes, following exposure to an allergen including foods, medicines, latex, and insect bites or stings. EpiPen®s are sold in packs of two, expire, and must be replaced on an annual basis.

As alleged, the need for many families to have one or more EpiPen®s on hand is hard to overstate. According to Food Allergy Research & Education—an allergy advocacy and research group— approximately 15 million people have food allergies in the United States and allergic reactions account for about 200,000 emergency room visits per year.

When someone has a severe allergic reaction, he or she must promptly inject themselves or be injected with epinephrine to prevent anaphylactic shock. Anaphylactic shock can kill, so having handy, pre-measured, pre-loaded epinephrine in a portable EpiPen® can be lifesaving.

Mylan is the only company selling EpiPen®s, and it has increased the price of its product more than 500% since 2007 when it began selling the device, which originally cost just $94.00 for a two-pack. While the EpiPen® reportedly costs Mylan just $34.501 to produce, today it sells the EpiPen® for a staggering amount: $600 or more for a two-pack.

Plaintiffs bring this consumer class action individually and on behalf of a putative nationwide class, as defined below (hereinafter “the Class”). Plaintiffs seek declaratory and injunctive relief, and to recover drug payments and overpayments made from at least the year 2007 through the present (hereinafter the “relevant time period”), as a result of Defendants’ unlawful scheme involving unfair, exorbitant, and unconscionable price increases.

This case concerns all EpiPen® products manufactured and distributed by Defendants including the following:

  1. EpiPen®;
  2. EpiPen Jr.®;
  3. EpiPen 2-Pak®;
  4. EpiPen Jr. 2-Pak®;
  5. My EpiPen®;
  7. Be Pepared®;
  8. EpiPen4Schools®
  9. Never-See-Needle®.



Kelly C. said
926 days ago
I had a severe allergic reaction on Wednesday, January 4, 2017 and went to St. Elizabeth Hospital in Fort Thomas, KY where my life was saved by injecting Epiphendrine. My physician wrote a prescription for it because I need to carry one on me at all times if/when it ever happens again. However, I cannot get it filled because the cost is $395 even with my Humana insurance.

Please help.

Ryan G. said
922 days ago

Jenny P. said
902 days ago
I have been appalled by the price increase of my epipens over the years.

Isabell D. said
843 days ago
I have just learned of the recall of possibly defective EpiPens which I have in my possession! NDC 49502-500-02 Lot# 6GM081 expiration date Sep 17

Submit a Response Are you having the same issue? Do you have a solution? Either way, chime in!

I would like to speak with a lawyer about my legal rights in this matter.

Same or similar issue but with a different company?

I would like to join the lawsuit.

Sign up for the Got a Class Action newsletter?

I have read and agree to the Terms and Conditions.

Contact A Lawyer Privately

  • This field is for validation purposes and should be left unchanged.